News | May 28, 2021
Remdesivir demand was exaggerated: Dr. Sharvil Patel
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Dr. Reddy's has the rights to distribute 250mn doses in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Subscribe To Our Newsletter & Stay Updated
